TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration
Brief Summary: This is a phase III, multicenter, randomized, double-masked, active treatment-controlled study of intravitreally administered ranibizumab compared with verteporfin (Visudyne) photodynamic therapy (PDT) in treating subfoveal neovascular mascular degeneration.


Options:
A: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Lucentis (Ranibizumab); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab (Lucentis) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab (Lucentis) | Intervention Type: DRUG; Name: Ranibizumab (Lucentis); Assigned to Arm(s): 1, 2
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Comparative, Open Label Phase III Trial on Efficacy & Safety of Long-term Treatment With ICL670 Compared to Deferoxamine in Beta-thalassemia Patients With Transfusional Hemosiderosis
Brief Summary: The purpose of this study is to deterimine if the new orally active iron chelator, ICL670, is as effective and as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.


Options:
A: Arm Label: Deferiprone + Desferrioxamine; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (L1), Drug: Desferrioxamine | Arm Label: Deferiprone single agent; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (L1) | Arm Label: Desferrioxamine single agent; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desferrioxamine | Intervention Type: DRUG; Name: Deferiprone (L1); Assigned to Arm(s): Deferiprone + Desferrioxamine, Deferiprone single agent | Intervention Type: DRUG; Name: Desferrioxamine; Assigned to Arm(s): Deferiprone + Desferrioxamine, Desferrioxamine single agent
B: Arm Label: ICL670; Type: EXPERIMENTAL; Interventions: Drug: ICL670 | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: deferoxamine | Intervention Type: DRUG; Name: ICL670; Assigned to Arm(s): ICL670 | Intervention Type: DRUG; Name: deferoxamine; Assigned to Arm(s): Deferoxamine
C: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Core Study: Deferasirox, Drug: Deferasirox | Arm Label: Deferasirox Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Core Study: Deferoxamine, Drug: Deferoxamine | Arm Label: Extension: deferoxamine to deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferoxamine to deferasirox | Arm Label: Extension: deferasirox to deferoxamine; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Core Study: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Core Study: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo | Intervention Type: DRUG; Name: Extension: deferoxamine to deferasirox; Assigned to Arm(s): Extension: deferoxamine to deferasirox | Intervention Type: DRUG; Name: Extension: deferasirox to deferoxamine; Assigned to Arm(s): Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo
D: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Comparative, Open Label Phase III Trial on Efficacy & Safety of Long-term Treatment With ICL670 Compared to Deferoxamine in Beta-thalassemia Patients With Transfusional Hemosiderosis
Brief Summary: The purpose of this study is to deterimine if the new orally active iron chelator, ICL670, is as effective and as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.


Options:
A: Arm Label: Deferiprone + Desferrioxamine; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (L1), Drug: Desferrioxamine | Arm Label: Deferiprone single agent; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (L1) | Arm Label: Desferrioxamine single agent; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desferrioxamine | Intervention Type: DRUG; Name: Deferiprone (L1); Assigned to Arm(s): Deferiprone + Desferrioxamine, Deferiprone single agent | Intervention Type: DRUG; Name: Desferrioxamine; Assigned to Arm(s): Deferiprone + Desferrioxamine, Desferrioxamine single agent
B: Intervention Type: DRUG; Name: deferiprone; Assigned to Arm(s): N/A
C: Arm Label: ICL670; Type: EXPERIMENTAL; Interventions: Drug: ICL670 | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: deferoxamine | Intervention Type: DRUG; Name: ICL670; Assigned to Arm(s): ICL670 | Intervention Type: DRUG; Name: deferoxamine; Assigned to Arm(s): Deferoxamine
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferiprone (DFP) | Intervention Type: DRUG; Name: Deferiprone (DFP) and Deferoxamine (DFO); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Deferiprone (DFP); Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Comparative, Open Label Phase III Trial on Efficacy & Safety of Long-term Treatment With ICL670 Compared to Deferoxamine in Beta-thalassemia Patients With Transfusional Hemosiderosis
Brief Summary: The purpose of this study is to deterimine if the new orally active iron chelator, ICL670, is as effective and as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.


Options:
A: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox, Radiation: HIDA | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Single Arm | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Single Arm | Intervention Type: RADIATION; Name: HIDA; Assigned to Arm(s): Single Arm
B: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox
C: Arm Label: arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670) | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP, DFO | Intervention Type: DRUG; Name: DFP (ferriprox) and deferasirox (ICL 670); Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: DFP, DFO; Assigned to Arm(s): arm 2
D: Arm Label: ICL670; Type: EXPERIMENTAL; Interventions: Drug: ICL670 | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: deferoxamine | Intervention Type: DRUG; Name: ICL670; Assigned to Arm(s): ICL670 | Intervention Type: DRUG; Name: deferoxamine; Assigned to Arm(s): Deferoxamine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind Study to Evaluate the Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
Brief Summary: A study to evaluate the efficacy and safety of two atypical antipsychotics vs. placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: asenapine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Intervention Type: DRUG; Name: asenapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
C: Arm Label: 80 milligrams (mg) LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 40 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 10 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 mg LY2140023, BID, 40 mg LY2140023, BID, 80 milligrams (mg) LY2140023, BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: risperidone, quetiapine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This project will determine whether exposing youths to a "fitogenic" after-school environment that emphasizes vigorous exercise and healthy snacks will have a favorable effect on body composition (i.e., less fat tissue and more lean tissue), cardiovascular fitness and cardiovascular disease risk profile. The environmental intervention will be provided in nine schools in Augusta, Georgia, with another nine schools serving as non-intervention comparison schools. Children in the 3rd grade will be recruited to participate. They will be followed for 3 years, through the 5th grade. Measurements will be made at the beginning and end of each school year. The 2-hour after-school intervention will be offered every school day. It will consist of three components: (1) homework assistance; (2) a healthy snack; and (3) exercise designed to improve skills and fitness.


Options:
A: Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A
B: Arm Label: SCORES; Type: EXPERIMENTAL; Interventions: Behavioral: America SCORES, Bay Area | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: America SCORES, Bay Area; Assigned to Arm(s): SCORES
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Policy and Environmental Change; Type: EXPERIMENTAL; Interventions: Behavioral: Policy and Environmental Change | Intervention Type: BEHAVIORAL; Name: Policy and Environmental Change; Assigned to Arm(s): Policy and Environmental Change
D: Arm Label: Intervention; Type: OTHER; Interventions: Behavioral: Healthy Eating and Physical Activity | Intervention Type: BEHAVIORAL; Name: Healthy Eating and Physical Activity; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This project will determine whether exposing youths to a "fitogenic" after-school environment that emphasizes vigorous exercise and healthy snacks will have a favorable effect on body composition (i.e., less fat tissue and more lean tissue), cardiovascular fitness and cardiovascular disease risk profile. The environmental intervention will be provided in nine schools in Augusta, Georgia, with another nine schools serving as non-intervention comparison schools. Children in the 3rd grade will be recruited to participate. They will be followed for 3 years, through the 5th grade. Measurements will be made at the beginning and end of each school year. The 2-hour after-school intervention will be offered every school day. It will consist of three components: (1) homework assistance; (2) a healthy snack; and (3) exercise designed to improve skills and fitness.


Options:
A: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling; Assigned to Arm(s): Lifestyle counseling
B: Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A
C: Arm Label: Movi2 Program; Type: EXPERIMENTAL; Interventions: Behavioral: Movi2 Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Movi2 Program; Assigned to Arm(s): Movi2 Program
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: MOVI-KIDS Program; Type: EXPERIMENTAL; Interventions: Behavioral: MOVI-KIDS | Intervention Type: BEHAVIORAL; Name: MOVI-KIDS; Assigned to Arm(s): MOVI-KIDS Program

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Intensity Modulated Radiotherapy Dose Escalation Trial for Prostate Cancer Using Hypofractionation
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays and other sources of radiation to kill tumor cells. It is not yet known which radiation therapy regimen is more effective in treating prostate cancer.

PURPOSE: This randomized phase III trial is comparing two different regimens of radiation therapy to see how well they work in treating patients with stage II or stage III prostate cancer.


Options:
A: Arm Label: Arm I: Sulfasalazine; Type: EXPERIMENTAL; Interventions: Drug: sulfasalazine | Arm Label: Arm II: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: sulfasalazine; Assigned to Arm(s): Arm I: Sulfasalazine | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II: Placebo
B: Arm Label: protons; Type: EXPERIMENTAL; Interventions: Procedure: radiation | Arm Label: carbon ions; Type: EXPERIMENTAL; Interventions: Procedure: radiation | Intervention Type: PROCEDURE; Name: radiation; Assigned to Arm(s): carbon ions, protons
C: Arm Label: CIMRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: radiation therapy | Arm Label: HIMRT; Type: EXPERIMENTAL; Interventions: Radiation: radiation therapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): CIMRT, HIMRT
D: Arm Label: Bifilact® probiotics standard dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bifilact® | Arm Label: Bifilact® probiotics high dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bifilact® | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: Bifilact®; Assigned to Arm(s): Bifilact® probiotics high dose, Bifilact® probiotics standard dose | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Van Gogh-PE Trial, a Multicenter, International, Randomized, Open-Label, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous SR34006 With the Combination of (LMW)Heparin and Vitamin K Antagonist (VKA) in the Treatment of Acute Symptomatic Pulmonary Embolism
Brief Summary: Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, SR34006, with the standard way of treating a pulmonary embolism. The standard treatment includes injections or infusions of an anticoagulant drug, (LMW)heparin, for about a week followed by anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth.

Assignment to either SR34006 or (LMW)heparin plus warfarin or acenocoumarol will be purely by chance and will be known by both patients and their doctors.


Options:
A: Intervention Type: DRUG; Name: SR34006; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: (LMW)heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Warfarin VKA; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acenocoumarol VKA; Assigned to Arm(s): N/A
B: Arm Label: Fondaparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Idrabiotaparinux; Type: EXPERIMENTAL; Interventions: Drug: Idrabiotaparinux sodium, Drug: Avidin, Drug: Placebo (for Avidin) | Arm Label: Idraparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Idraparinux sodium, Drug: Placebo (for Avidin) | Intervention Type: DRUG; Name: Idrabiotaparinux sodium; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Idraparinux sodium; Assigned to Arm(s): Idraparinux | Intervention Type: DRUG; Name: Avidin; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Placebo (for Avidin); Assigned to Arm(s): Idrabiotaparinux, Idraparinux
D: Arm Label: SRI 15mg (15 mL/min ≤ CLCR < 20mL/min); Type: EXPERIMENTAL; Interventions: Drug: 15mg DU-176b | Arm Label: MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min); Type: EXPERIMENTAL; Interventions: Drug: 30mg DU-176b | Arm Label: Fondaparinux (20 mL/min ≤ CLCR < 30mL/min); Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Arm Label: SRI 15mg (20 mL/min ≤ CLCR < 30mL/min); Type: EXPERIMENTAL; Interventions: Drug: 15mg DU-176b | Intervention Type: DRUG; Name: 15mg DU-176b; Assigned to Arm(s): SRI 15mg (15 mL/min ≤ CLCR < 20mL/min), SRI 15mg (20 mL/min ≤ CLCR < 30mL/min) | Intervention Type: DRUG; Name: 30mg DU-176b; Assigned to Arm(s): MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min) | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux (20 mL/min ≤ CLCR < 30mL/min)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Van Gogh-PE Trial, a Multicenter, International, Randomized, Open-Label, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous SR34006 With the Combination of (LMW)Heparin and Vitamin K Antagonist (VKA) in the Treatment of Acute Symptomatic Pulmonary Embolism
Brief Summary: Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, SR34006, with the standard way of treating a pulmonary embolism. The standard treatment includes injections or infusions of an anticoagulant drug, (LMW)heparin, for about a week followed by anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth.

Assignment to either SR34006 or (LMW)heparin plus warfarin or acenocoumarol will be purely by chance and will be known by both patients and their doctors.


Options:
A: Arm Label: Idrabiotaparinux; Type: EXPERIMENTAL; Interventions: Drug: Idrabiotaparinux sodium, Drug: Avidin, Drug: Placebo (for warfarin), Drug: Enoxaparin | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Placebo (for idrabiotaparinux sodium), Drug: Avidin, Drug: Enoxaparin | Intervention Type: DRUG; Name: Idrabiotaparinux sodium; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Placebo (for idrabiotaparinux sodium); Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Avidin; Assigned to Arm(s): Idrabiotaparinux, Warfarin | Intervention Type: DRUG; Name: Placebo (for warfarin); Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Idrabiotaparinux, Warfarin
B: Arm Label: Idrabiotaparinux; Type: EXPERIMENTAL; Interventions: Drug: Idrabiotaparinux sodium, Drug: Avidin, Drug: Placebo (for Avidin) | Arm Label: Idraparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Idraparinux sodium, Drug: Placebo (for Avidin) | Intervention Type: DRUG; Name: Idrabiotaparinux sodium; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Idraparinux sodium; Assigned to Arm(s): Idraparinux | Intervention Type: DRUG; Name: Avidin; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Placebo (for Avidin); Assigned to Arm(s): Idrabiotaparinux, Idraparinux
C: Intervention Type: DRUG; Name: SanOrg34006; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: LMW heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin K antagonist (VKA); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: SR34006; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: (LMW)heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Warfarin VKA; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acenocoumarol VKA; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Generic Database: A Survey of Morbidity and Mortality in Very Low Birth Weight Infants
Brief Summary: The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.


Options:
A: Arm Label: Registry Cohort; Type: N/A; Interventions: Other: No Intervention | Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): Registry Cohort
B: Arm Label: Maternal voice; Type: EXPERIMENTAL; Interventions: Other: Maternal voice | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Maternal voice; Assigned to Arm(s): Maternal voice
C: Arm Label: Early Vocal Contact; Type: EXPERIMENTAL; Interventions: Behavioral: Early Vocal Contact | Arm Label: Behavioral observation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Observation | Intervention Type: BEHAVIORAL; Name: Early Vocal Contact; Assigned to Arm(s): Early Vocal Contact | Intervention Type: BEHAVIORAL; Name: Behavioral Observation; Assigned to Arm(s): Behavioral observation
D: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Other: NeuroN-QI | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: NeuroN-QI; Assigned to Arm(s): Experimental

Answer: A